➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
AstraZeneca
McKinsey
Express Scripts
Mallinckrodt

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Insulin detemir - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for insulin detemir

Identify potential brand extensions & biosimilar entrants

SponsorPhase
First Affiliated Hospital Xi'an Jiaotong UniversityN/A
Minneapolis Medical Research FoundationN/A
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPhase 3

See all insulin detemir clinical trials

Recent Litigation for insulin detemir

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08
Purdue Pharmaceutical v. Actavis Elizabeth LLC2015-05-13

See all insulin detemir litigation

Pharmacology for insulin detemir
Ingredient-typeInsulin
Established Pharmacologic ClassInsulin Analog
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin detemir Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin detemir Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 ⤷  Free Forever Trial 2008-02-10 Company disclosures
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 ⤷  Free Forever Trial 2014-04-08 Company disclosures
Novo Nordisk Inc. LEVEMIR insulin detemir Injection 021536 ⤷  Free Forever Trial 2015-05-12 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for insulin detemir Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for insulin detemir

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004C/020 Belgium ⤷  Free Forever Trial PRODUCT NAME: INSULIN DETEMIR; AUTHORISATION NUMBER AND DATE: 56370 01 20040601
SPC015/2004 Ireland ⤷  Free Forever Trial SPC015/2004, 20060131, EXPIRES: 20181109
SZ 28/2004 Austria ⤷  Free Forever Trial PRODUCT NAME: INSULIN-DETEMIR UND PHARMAZEUTISCH ANNEHMBARE ZN-SALZE DAVON
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Colorcon
Merck
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.